SI0792290T1 - Acylated insulin - Google Patents

Acylated insulin

Info

Publication number
SI0792290T1
SI0792290T1 SI9430396T SI9430396T SI0792290T1 SI 0792290 T1 SI0792290 T1 SI 0792290T1 SI 9430396 T SI9430396 T SI 9430396T SI 9430396 T SI9430396 T SI 9430396T SI 0792290 T1 SI0792290 T1 SI 0792290T1
Authority
SI
Slovenia
Prior art keywords
amino acid
acid residue
lys
present
cys
Prior art date
Application number
SI9430396T
Other languages
English (en)
Inventor
Svend Havelund
John Broberg Halstrom
Ib Jonassen
Asser Sloth Andersen
Jan Markussen
Original Assignee
Novo Nordisk As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26065125&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SI0792290(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from DK104493A external-priority patent/DK104493D0/da
Application filed by Novo Nordisk As filed Critical Novo Nordisk As
Publication of SI0792290T1 publication Critical patent/SI0792290T1/xx

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/01DNA viruses
    • C07K14/02Hepadnaviridae, e.g. hepatitis B virus
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575Hormones
    • C07K14/62Insulins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22Hormones
    • A61K38/28Insulins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
SI9430396T 1993-09-17 1994-09-16 Acylated insulin SI0792290T1 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
DK104493A DK104493D0 (da) 1993-09-17 1993-09-17 Hidtil ukendte peptider
US19082994A 1994-02-02 1994-02-02
EP94926816A EP0792290B1 (fr) 1993-09-17 1994-09-16 Insuline acylee
PCT/DK1994/000347 WO1995007931A1 (fr) 1993-09-17 1994-09-16 Insuline acylee

Publications (1)

Publication Number Publication Date
SI0792290T1 true SI0792290T1 (en) 2001-12-31

Family

ID=26065125

Family Applications (1)

Application Number Title Priority Date Filing Date
SI9430396T SI0792290T1 (en) 1993-09-17 1994-09-16 Acylated insulin

Country Status (30)

Country Link
US (1) US5750497A (fr)
EP (2) EP0792290B1 (fr)
JP (3) JP3014764B2 (fr)
KR (1) KR100310122B1 (fr)
CN (1) CN1056618C (fr)
AT (1) ATE204882T1 (fr)
AU (2) AU682061B2 (fr)
BG (1) BG61611B1 (fr)
BR (1) BR9407508A (fr)
CA (1) CA2171424C (fr)
CZ (1) CZ287945B6 (fr)
DE (2) DE69428134T2 (fr)
DK (1) DK0792290T3 (fr)
ES (1) ES2163451T3 (fr)
FI (1) FI117055B (fr)
FR (1) FR04C0020I2 (fr)
HU (1) HU217684B (fr)
IL (1) IL110977A (fr)
LU (1) LU91101I2 (fr)
NL (1) NL300160I2 (fr)
NO (3) NO316944B1 (fr)
NZ (1) NZ273285A (fr)
PL (1) PL178466B1 (fr)
PT (1) PT792290E (fr)
RO (1) RO112873B1 (fr)
RU (1) RU2164520C2 (fr)
SI (1) SI0792290T1 (fr)
SK (1) SK282495B6 (fr)
UA (1) UA45321C2 (fr)
WO (1) WO1995007931A1 (fr)

Families Citing this family (184)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9316895D0 (en) * 1993-08-13 1993-09-29 Guy S And St Thomas Hospitals Hepatoselective insulin analogues
US6342225B1 (en) 1993-08-13 2002-01-29 Deutshces Wollforschungsinstitut Pharmaceutical active conjugates
US6869930B1 (en) * 1993-09-17 2005-03-22 Novo Nordisk A/S Acylated insulin
DE4437604A1 (de) * 1994-10-21 1996-04-25 Basf Ag Konjugate aus einem Poly- oder Oligopeptid und einer niedermolekularen lipophilen Verbindung
US5646242A (en) 1994-11-17 1997-07-08 Eli Lilly And Company Selective acylation of epsilon-amino groups
US5693609A (en) * 1994-11-17 1997-12-02 Eli Lilly And Company Acylated insulin analogs
DE69629210T2 (de) * 1995-03-17 2004-04-22 Novo Nordisk A/S Insulinabkömmlinge
US6251856B1 (en) 1995-03-17 2001-06-26 Novo Nordisk A/S Insulin derivatives
US20010041786A1 (en) * 1995-06-07 2001-11-15 Mark L. Brader Stabilized acylated insulin formulations
GB9513967D0 (en) * 1995-07-08 1995-09-06 Univ Leicester Insulin
US6451970B1 (en) 1996-02-21 2002-09-17 Novo Nordisk A/S Peptide derivatives
RU2182015C2 (ru) * 1996-06-20 2002-05-10 Ново Нордиск А/С ПРЕПАРАТ ИНСУЛИНА, СОДЕРЖАЩИЙ NaCl, ПАРЕНТЕРАЛЬНАЯ ГОТОВАЯ ФОРМА, СПОСОБ ПОВЫШЕНИЯ ХИМИЧЕСКОЙ СТАБИЛЬНОСТИ ПРЕПАРАТА ИНСУЛИНА
AU3255297A (en) * 1996-07-11 1998-02-09 Novo Nordisk A/S Selective acylation method
US5905140A (en) * 1996-07-11 1999-05-18 Novo Nordisk A/S, Novo Alle Selective acylation method
US20020025933A1 (en) * 1996-08-30 2002-02-28 Knudsen Liselotte Bjerre GLP-2 derivatives
US6268343B1 (en) 1996-08-30 2001-07-31 Novo Nordisk A/S Derivatives of GLP-1 analogs
US6458924B2 (en) 1996-08-30 2002-10-01 Novo Nordisk A/S Derivatives of GLP-1 analogs
US7235627B2 (en) 1996-08-30 2007-06-26 Novo Nordisk A/S Derivatives of GLP-1 analogs
US5898067A (en) * 1997-02-07 1999-04-27 Novo Nordisk A/S Crystallization of proteins
US6310038B1 (en) * 1997-03-20 2001-10-30 Novo Nordisk A/S Pulmonary insulin crystals
US6043214A (en) * 1997-03-20 2000-03-28 Novo Nordisk A/S Method for producing powder formulation comprising an insulin
JP3764174B2 (ja) * 1997-03-20 2006-04-05 ノボ ノルディスク アクティーゼルスカブ 肺用組成物において使用するための亜鉛非含有のインスリン結晶
US6451762B1 (en) 1997-10-24 2002-09-17 Novo Nordisk A/S Aggregates of human insulin derivatives
US6444641B1 (en) 1997-10-24 2002-09-03 Eli Lilly Company Fatty acid-acylated insulin analogs
ZA989644B (en) * 1997-10-24 2000-04-25 Lilly Co Eli Insoluble insulen compositions.
IL134901A0 (en) 1997-10-24 2001-05-20 Lilly Co Eli Insoluble insulin compositions
ZA989744B (en) * 1997-10-31 2000-04-26 Lilly Co Eli Method for administering acylated insulin.
EP1396272A1 (fr) * 1997-12-23 2004-03-10 Eli Lilly & Company Compositions insolubles d'insuline pour le contrôle du glucose sanguin
US6531448B1 (en) 1997-12-23 2003-03-11 Eli Lilly And Company Insoluble compositions for controlling blood glucose
DE69924232D1 (de) * 1998-01-09 2005-04-21 Novo Nordisk As Stabilisierte insulin-zubereitungen
JP2002504527A (ja) * 1998-02-27 2002-02-12 ノボ ノルディスク アクティーゼルスカブ 部分的に組織化したミセル様凝集物を形成する25%を越えるヘリックス成分を有するglp−2誘導体
DE19825447A1 (de) * 1998-06-06 1999-12-09 Hoechst Marion Roussel De Gmbh Neue Insulinanaloga mit erhöhter Zinkbildung
WO1999065941A1 (fr) * 1998-06-12 1999-12-23 Kings College London Analogue de l'insuline
US7169889B1 (en) * 1999-06-19 2007-01-30 Biocon Limited Insulin prodrugs hydrolyzable in vivo to yield peglylated insulin
ES2266187T3 (es) 2000-03-24 2007-03-01 Genentech, Inc. Uso de la insulina para el tratamiento de trastornos del cartilago.
JP2003532691A (ja) * 2000-05-05 2003-11-05 ノボ ノルディスク アクティーゼルスカブ 重症疾患神経障害
US7316999B2 (en) 2000-06-02 2008-01-08 Novo Nordisk A/S Glucose dependent release of insulin from glucose sensing insulin derivatives
WO2002004515A1 (fr) * 2000-07-10 2002-01-17 Btg International Limited Derives d'insuline et synthese desdits derives
KR20030005204A (ko) * 2000-12-25 2003-01-17 가부시키가이샤 시세이도 교감신경 활성화 향료 조성물
US7060675B2 (en) * 2001-02-15 2006-06-13 Nobex Corporation Methods of treating diabetes mellitus
US6867183B2 (en) * 2001-02-15 2005-03-15 Nobex Corporation Pharmaceutical compositions of insulin drug-oligomer conjugates and methods of treating diseases therewith
US6653492B2 (en) 2001-05-02 2003-11-25 Novo Nordick A/S Preparation of bile acids
EP1698636A1 (fr) * 2001-05-02 2006-09-06 Novo Nordisk A/S Procédé de préparation de conjagates de peptides avec des acides biliaire
US6828305B2 (en) * 2001-06-04 2004-12-07 Nobex Corporation Mixtures of growth hormone drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
US7713932B2 (en) * 2001-06-04 2010-05-11 Biocon Limited Calcitonin drug-oligomer conjugates, and uses thereof
US6858580B2 (en) * 2001-06-04 2005-02-22 Nobex Corporation Mixtures of drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
US6828297B2 (en) 2001-06-04 2004-12-07 Nobex Corporation Mixtures of insulin drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
US6713452B2 (en) * 2001-06-04 2004-03-30 Nobex Corporation Mixtures of calcitonin drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
US6835802B2 (en) * 2001-06-04 2004-12-28 Nobex Corporation Methods of synthesizing substantially monodispersed mixtures of polymers having polyethylene glycol moieties
US7595172B2 (en) 2001-07-24 2009-09-29 Novo Nordisk A/S Method for making acylated polypeptides
MXPA04001560A (es) 2001-08-28 2004-05-17 Lilly Co Eli Premezclas de glp-1 e insulina basal.
US7176278B2 (en) 2001-08-30 2007-02-13 Biorexis Technology, Inc. Modified transferrin fusion proteins
MY127575A (en) 2001-09-07 2006-12-29 Biocon Ltd Methods of synthesizing insulin polypeptide-oligomer conjugates, and proinsulin polypeptide-oligomer conjugates and methods of synthesizing same
US6913903B2 (en) * 2001-09-07 2005-07-05 Nobex Corporation Methods of synthesizing insulin polypeptide-oligomer conjugates, and proinsulin polypeptide-oligomer conjugates and methods of synthesizing same
US7312192B2 (en) * 2001-09-07 2007-12-25 Biocon Limited Insulin polypeptide-oligomer conjugates, proinsulin polypeptide-oligomer conjugates and methods of synthesizing same
US7166571B2 (en) * 2001-09-07 2007-01-23 Biocon Limited Insulin polypeptide-oligomer conjugates, proinsulin polypeptide-oligomer conjugates and methods of synthesizing same
US7196059B2 (en) * 2001-09-07 2007-03-27 Biocon Limited Pharmaceutical compositions of insulin drug-oligomer conjugates and methods of treating diseases therewith
EP2243776A1 (fr) 2001-10-12 2010-10-27 High Point Pharmaceuticals, LLC Piperidines substituées et leur utilisation dans le traitement de maladies liées au recepteur histaminique H3
WO2003035099A1 (fr) 2001-10-19 2003-05-01 Eli Lilly And Company Melanges biphasiques de glp-1 et d'insuline
DE60236014D1 (de) 2001-11-19 2010-05-27 Novo Nordisk As Verfahren zur herstellung von insulinverbindungen
GB0206792D0 (en) 2002-03-22 2002-05-01 Leuven K U Res & Dev Normoglycemia
ES2360182T3 (es) * 2002-05-07 2011-06-01 Novo Nordisk A/S Formulaciones solubles que comprenden insulina monomérica e insulina acilada.
US20040038864A1 (en) * 2002-06-27 2004-02-26 Per Balschmidt Use of dimethyl sulfone as isotonicity agent
KR101131783B1 (ko) * 2002-09-25 2012-03-30 노보 노르디스크 에이/에스 아실화된 펩타이드의 제조방법
US7273921B2 (en) 2002-09-25 2007-09-25 Novo Nordisk A/S Method for producing acylated peptides
WO2004035624A2 (fr) 2002-10-14 2004-04-29 Novo Nordisk A/S Composes glp-2, leurs formulations et leurs utilisations
US20040138099A1 (en) * 2002-11-29 2004-07-15 Draeger Eberhard Kurt Insulin administration regimens for the treatment of subjects with diabetes
WO2004085472A1 (fr) * 2003-03-27 2004-10-07 Novo Nordisk A/S Procede de fabrication de precurseurs de l'insuline humaine et insuline humaine
JP4629657B2 (ja) 2003-04-11 2011-02-09 ハイ・ポイント・ファーマスーティカルズ、エルエルシー 11β−ヒドロキシステロイドデヒドロゲナーゼ1型化活性化合物
WO2004096266A1 (fr) * 2003-05-02 2004-11-11 Novo Nordisk A/S Stabilite physique amelioree de preparations d'insuline
RU2381103C2 (ru) 2003-06-27 2010-02-10 Ново Нордиск А/С Контейнер для жидких фармацевтических композиций с высокими влагозащитными свойствами
JP4463814B2 (ja) 2003-08-05 2010-05-19 ノボ ノルディスク アクティーゼルスカブ 新規のインスリン誘導体
EP2264066A3 (fr) 2003-08-05 2011-07-27 Novo Nordisk A/S Nouveaux derives de l'insuline
JP2007532096A (ja) 2003-11-14 2007-11-15 ノボ ノルディスク アクティーゼルスカブ アシル化されたインスリンの製造方法
ES2727854T3 (es) 2003-11-20 2019-10-21 Novo Nordisk As Formulaciones de péptidos que contienen propilenglicol que son óptimas para la producción y para su uso en dispositivos de inyección
AU2004295023A1 (en) 2003-12-03 2005-06-16 Novo Nordisk A/S Single-chain insulin
ATE483580T1 (de) 2003-12-22 2010-10-15 Novo Nordisk As Durchsichtiger, flexibler, undurchlässiger kunststoffbehälter zur lagerung von pharmazeutischen flüssigkeiten
CN1909930B (zh) 2004-01-21 2015-12-16 诺和诺德医疗保健公司 转谷氨酰胺酶介导的肽的接合
PT2319500E (pt) * 2004-03-12 2013-01-23 Biodel Inc Composições de distribuição de fármacos de actuação rápida
WO2006008238A1 (fr) * 2004-07-16 2006-01-26 Novo Nordisk A/S Procede d'acylation selective
US7872095B2 (en) * 2004-07-19 2011-01-18 Biocon Limited Insulin-oligomer conjugates, formulations and uses thereof
US7833513B2 (en) 2004-12-03 2010-11-16 Rhode Island Hospital Treatment of Alzheimer's Disease
WO2006082204A1 (fr) 2005-02-02 2006-08-10 Novo Nordisk A/S Derives d'insuline
EP2292653B1 (fr) 2005-02-02 2014-05-21 Novo Nordisk A/S Nouveaux dérivés d'insuline
JP5235661B2 (ja) 2005-05-25 2013-07-10 ノボ・ノルデイスク・エー/エス 安定化ポリペプチド製剤
JP2008542235A (ja) * 2005-05-25 2008-11-27 ノボ・ノルデイスク・エー/エス 安定化ポリペプチド製剤
EP1888104A2 (fr) * 2005-05-26 2008-02-20 Novo Nordisk A/S Insuline acylee tres pure
WO2007003604A2 (fr) 2005-07-04 2007-01-11 Novo Nordisk A/S Medicaments
WO2007015805A1 (fr) 2005-07-20 2007-02-08 Eli Lilly And Company Composés joints en position 1-amino
US9056921B2 (en) 2005-08-16 2015-06-16 Novo Nordisk A/S Method for making mature insulin polypeptides
US7741281B2 (en) * 2005-11-03 2010-06-22 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
PT1951658E (pt) 2005-11-17 2012-11-12 Lilly Co Eli Antagonistas do receptor do glucagon, preparação e utilizações terapêuticas
CN101389650B (zh) 2005-12-28 2012-10-10 诺沃-诺迪斯克有限公司 包含酰化胰岛素和锌的组合物以及制备所述组合物的方法
JP5242415B2 (ja) * 2006-01-18 2013-07-24 フォアシーエイサー ファーマシューティカルズ インコーポレイテッド 高い安定性を持つ薬理組成物
ATE482977T1 (de) 2006-02-27 2010-10-15 Novo Nordisk As Insulinderivate
WO2007104737A1 (fr) * 2006-03-13 2007-09-20 Novo Nordisk A/S Insuline monocaténaire acylée
EP2241327A1 (fr) 2006-03-15 2010-10-20 Novo Nordisk A/S Melange d'amyline et d'insuline
ES2388681T3 (es) 2006-03-28 2012-10-17 High Point Pharmaceuticals, Llc Benzotiazoles con actividad de los receptores de histamina H3
CA2649111C (fr) 2006-04-24 2013-09-10 Eli Lilly And Company Pyrrolidinones substtuees a la cyclohexyle comme inhibiteurs de la 11-beta-hydroxysteroide dehydrogenase de type 1
US8796205B2 (en) 2006-05-09 2014-08-05 Novo Nordisk A/S Insulin derivative
CN101437849B (zh) * 2006-05-09 2015-09-30 诺沃-诺迪斯克有限公司 胰岛素衍生物
WO2007128817A2 (fr) * 2006-05-09 2007-11-15 Novo Nordisk A/S Dérivé insulinique
US7714025B2 (en) * 2006-05-10 2010-05-11 Arizona Biomedical Research Commission Modified chalcone compounds as antimitotic agents
PL2079732T3 (pl) 2006-05-29 2012-05-31 High Point Pharmaceuticals Llc 3-(1,3-benzodioksol-5-ylo)-6-(4-cyklopropylopiperazyn-1-ylo)-pirydazyna, jej sole i solwaty oraz jej zastosowanie jako antagonisty receptora histaminowego h3
WO2008008363A1 (fr) 2006-07-11 2008-01-17 Qps, Llc Compositions pharmaceutiques pour délivrance à libération prolongée de peptides
WO2008015099A2 (fr) 2006-07-31 2008-02-07 Novo Nordisk A/S Insulines pegylées à extensions
CN101541830A (zh) 2006-09-22 2009-09-23 诺沃-诺迪斯克有限公司 蛋白酶抗性的胰岛素类似物
WO2008037735A1 (fr) 2006-09-27 2008-04-03 Novo Nordisk A/S Procédé de fabrication de polypeptides d'insuline mature
WO2008049711A1 (fr) * 2006-10-27 2008-05-02 Novo Nordisk A/S Insuline à peptide ajouté
EP2152245B1 (fr) 2007-04-30 2015-12-02 Novo Nordisk A/S Procédé de déshydratation d'une composition de protéine, composition de protéine déshydratée et composition pharmaceutique contenant la protéine déshydratée
EP2514406A1 (fr) 2007-06-01 2012-10-24 Novo Nordisk A/S Préconcentrés spontanément dispersibles comprenant un médicament peptidique dans un support solide ou semi-solide
EP2164459A1 (fr) 2007-06-01 2010-03-24 Novo Nordisk A/S Compositions pharmaceutiques non aqueuses stables
ES2744384T3 (es) 2007-06-13 2020-02-24 Novo Nordisk As Formulación farmacéutica que comprende un derivado de insulina
EP2178909B1 (fr) 2007-08-13 2015-10-21 Novo Nordisk A/S Analogues de l'insuline à action rapide
KR101234540B1 (ko) * 2007-10-16 2013-02-19 바이오콘 리미티드 경구 투여가능한 고형 약제학적 조성물 및 그 제조방법
WO2009060071A1 (fr) * 2007-11-08 2009-05-14 Novo Nordisk A/S Dérivé de l'insuline
EP2058330A1 (fr) * 2007-11-08 2009-05-13 Novo Nordisk A/S Dérivé d'insuline
CN107115523A (zh) 2007-11-16 2017-09-01 诺沃—诺迪斯克有限公司 包含glp‑1肽或毒蜥外泌肽‑4和基础胰岛素肽的药物组合物
US20090175840A1 (en) * 2008-01-04 2009-07-09 Biodel, Inc. Insulin formulations for insulin release as a function of tissue glucose levels
JP5762001B2 (ja) 2008-03-14 2015-08-12 ノボ・ノルデイスク・エー/エス プロテアーゼ安定化インスリンアナログ
US8691759B2 (en) 2008-03-18 2014-04-08 Novo Nordisk A/S Protease stabilized, acylated insulin analogues
TWI451876B (zh) 2008-06-13 2014-09-11 Lilly Co Eli 聚乙二醇化之離脯胰島素化合物
KR20110059602A (ko) 2008-08-07 2011-06-02 바이오콘 리미티드 인슐린 화합물의 제조방법
BRPI0919946A2 (pt) 2008-10-30 2016-02-16 Novo Nordisk As tratamento de diabetes melito usando injeções de insulina com frequência de injeção menor que diariamente
KR20110088575A (ko) 2008-11-21 2011-08-03 하이 포인트 파마슈티칼스, 엘엘씨 아다만틸 벤즈아미드 화합물
CA2750252A1 (fr) 2009-01-28 2010-08-05 Smartcells, Inc. Conjugues synthetiques et leurs utilisations
SG2014006597A (en) 2009-01-28 2014-04-28 Smartcells Inc Conjugate based systems for controlled drug delivery
US9060927B2 (en) * 2009-03-03 2015-06-23 Biodel Inc. Insulin formulations for rapid uptake
JP2012520879A (ja) 2009-03-20 2012-09-10 スマートセルズ・インコーポレイテツド 末端官能基化コンジュゲートおよびその用途
US20120134977A1 (en) 2009-06-01 2012-05-31 Yeda Research And Development Co. Ltd. Prodrugs containing albumin binding probe
JP5892940B2 (ja) 2009-11-25 2016-03-23 アリスジェン ソシエテ アノニム クラウン化合物及び/又は対イオンと複合体化されたペプチドを含む粘膜送達組成物
EP2460527A1 (fr) 2010-01-21 2012-06-06 Sanofi Composition pharmaceutique pour le traitement d'un syndrome métabolique
AR081066A1 (es) 2010-04-02 2012-06-06 Hanmi Holdings Co Ltd Conjugado de insulina donde se usa un fragmento de inmunoglobulina
US9981017B2 (en) 2010-04-02 2018-05-29 Hanmi Science Co., Ltd. Insulin conjugate using an immunoglobulin fragment
AR080884A1 (es) 2010-04-14 2012-05-16 Sanofi Aventis Conjugados de insulina-sirna
CN107029212A (zh) * 2010-05-10 2017-08-11 诺沃—诺迪斯克有限公司 用于制备胰岛素‑锌复合物的方法
EP2627670A2 (fr) * 2010-10-15 2013-08-21 Novo Nordisk A/S Nouveaux dérivés d'insuline à extrémité n modifiée
DK2632478T3 (da) 2010-10-27 2019-10-07 Novo Nordisk As Behandling af diabetes melitus under anvendelse af insulinindsprøjtninger indgivet med varierende indsprøjtningsintervaller
EP2654794B8 (fr) 2010-12-22 2020-04-22 Baxalta GmbH Matériels et méthodes pour la conjugaison d'un dérivé d'acide gras soluble dans l'eau à une protéine
KR20140043709A (ko) 2011-01-20 2014-04-10 질랜드 파마 에이/에스 아실화 글루카곤 유사체와 인슐린 유사체의 조합
US10130684B2 (en) 2011-02-03 2018-11-20 Pharmedica Ltd. Oral dissolving films for insulin administration, for treating diabetes
US9480751B2 (en) 2011-04-11 2016-11-01 Yeda Research And Development Co. Ltd. Albumin binding probes and drug conjugates thereof
EP2548570A1 (fr) 2011-07-19 2013-01-23 Sanofi Composition pharmaceutique pour le traitement d'un syndrome métabolique
CN102504022A (zh) * 2011-11-30 2012-06-20 苏州元基生物技术有限公司 含有保护赖氨酸的胰岛素原及使用其制备胰岛素的方法
EP2784085A4 (fr) * 2011-12-15 2015-07-08 Shanghai Hengrui Pharm Co Ltd Analogue d'insuline humaine et son dérivé acylé
BR112014025132A2 (pt) 2012-04-11 2017-07-11 Novo Nordisk As formulações de insulina
JP6262206B2 (ja) 2012-05-01 2018-01-17 ノヴォ ノルディスク アー/エス 医薬組成物
JP6735561B2 (ja) 2012-12-03 2020-08-05 メルク・シャープ・アンド・ドーム・コーポレーションMerck Sharp & Dohme Corp. O−グリコシル化カルボキシ末端部分(ctp)ペプチド系のインスリンおよびインスリン類似体
US10137172B2 (en) 2013-04-30 2018-11-27 Novo Nordisk A/S Administration regime
US10286078B2 (en) 2013-09-13 2019-05-14 The California Institute For Biomedical Research Modified therapeutic agents and compositions thereof
BR112016007166A2 (pt) 2013-10-07 2017-09-12 Novo Nordisk As derivado de um análogo de insulina
US10039809B2 (en) 2013-12-18 2018-08-07 The California Institute For Biomedical Research Modified therapeutic agents, stapled peptide lipid conjugates, and compositions thereof
AR099569A1 (es) 2014-02-28 2016-08-03 Novo Nordisk As Derivados de insulina y los usos médicos de estos
US9656017B2 (en) 2014-06-20 2017-05-23 Howard E. Greene Infusion delivery devices and methods
US20190000928A1 (en) 2015-06-17 2019-01-03 The California Institute For Biomedical Research Modified therapeutic agents and compositions thereof
US11352406B2 (en) 2015-08-25 2022-06-07 Novo Nordisk A/S Insulin derivatives and the medical uses hereof
US10815287B2 (en) 2016-08-02 2020-10-27 Jiangsu Hengrui Medicine Co., Ltd. Acylated derivative of human insulin or analogue thereof
JP2020504714A (ja) 2016-12-05 2020-02-13 ニューリタス リミテッド ペプチドwkdeagkplvkを含む組成物
EP3329930A1 (fr) 2016-12-05 2018-06-06 Nuritas Limited Compositions pharmaceutiques
JP6690062B2 (ja) 2016-12-16 2020-04-28 ノヴォ ノルディスク アー/エス インスリン含有医薬組成物
AU2018321157B2 (en) 2017-08-24 2024-03-28 Novo Nordisk A/S GLP-1 compositions and uses thereof
JP2020535199A (ja) * 2017-09-29 2020-12-03 ハンミ ファーマシューティカル カンパニー リミテッド 効力が向上した持続性タンパク質結合体
WO2019125878A1 (fr) 2017-12-18 2019-06-27 Merck Sharp & Dohme Corp. Systèmes à base de conjugués pour l'administration contrôlée d'insuline
WO2019125879A2 (fr) 2017-12-18 2019-06-27 Merck Sharp & Dohme Corp. Systèmes à base de conjugués pour l'administration contrôlée d'insuline
US20210032307A1 (en) 2018-02-09 2021-02-04 Jiangsu Hengrui Medicine Co., Ltd. Codon optimized precursor gene and signal peptide gene of human insulin analogue
AU2019272401A1 (en) 2018-05-24 2021-01-14 Jiangsu Hengrui Medicine Co., Ltd. Method for preparing precursor of recombinant human insulin or analogue thereof
US10335464B1 (en) 2018-06-26 2019-07-02 Novo Nordisk A/S Device for titrating basal insulin
KR20200017078A (ko) 2018-08-08 2020-02-18 주식회사 대웅제약 지속형 인슐린 아날로그 및 그 복합체
WO2020120479A1 (fr) 2018-12-11 2020-06-18 Sanofi Liant peptidique
KR20200080747A (ko) 2018-12-27 2020-07-07 주식회사 폴루스 인슐린 전구체의 인슐린 효소 전환용 조성물 및 이를 이용하여 인슐린 전구체를 인슐린으로 전환하는 방법
KR20200080748A (ko) 2018-12-27 2020-07-07 주식회사 폴루스 음이온 교환 크로마토그래피를 이용한 인슐린 전구체의 정제방법
CN111909255A (zh) * 2019-05-10 2020-11-10 宁波鲲鹏生物科技有限公司 胰岛素衍生物及其制备方法
TW202120536A (zh) 2019-07-31 2021-06-01 美商美國禮來大藥廠 鬆弛素(relaxin)類似物及其使用方法
MX2022006251A (es) 2019-12-11 2022-06-22 Novo Nordisk As Analogos de insulina novedosos y usos de estos.
CA3166496A1 (fr) 2019-12-30 2021-07-08 Gan & Lee Pharmaceuticals Co., Ltd. Compose glp-1 a action prolongee
AU2020417892A1 (en) 2019-12-30 2022-08-25 Gan & Lee Pharmaceuticals Co., Ltd. Insulin derivative
IL294520A (en) 2020-02-18 2022-09-01 Novo Nordisk As Pharmaceutical formulations
AU2021247169A1 (en) 2020-03-31 2022-10-20 Protomer Technologies Inc. Conjugates for selective responsiveness to vicinal diols
AU2021382599A1 (en) 2020-11-19 2023-06-22 Protomer Technologies Inc. Aromatic boron-containing compounds and insulin analogs
EP4299057A1 (fr) 2022-06-30 2024-01-03 Adocia Compositions solides comportant un peptide ou une protéine et un acide aminé acylé
EP4180060A1 (fr) 2021-11-15 2023-05-17 Adocia Compositions solides comportant un peptide ou une protéine et un acide aminé acylé
WO2023084118A1 (fr) 2021-11-15 2023-05-19 Adocia Compositions solides comprenant un peptide ou une protéine et un acide aminé acylé
EP4299071A1 (fr) 2022-07-01 2024-01-03 Adocia Compositions comprenant un peptide ou une protéine et un acide aminé acylé
WO2024051787A1 (fr) * 2022-09-09 2024-03-14 北京惠之衡生物科技有限公司 Dérivé d'insuline acylé à action prolongée et son utilisation

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3823125A (en) * 1969-10-14 1974-07-09 American Home Prod N-aminoacyl-substituted insulins
US3950517A (en) * 1970-05-08 1976-04-13 National Research Development Corporation Insulin derivatives
GB1381274A (en) * 1971-01-28 1975-01-22 Nat Res Dev Insulin derivatives
GB1381273A (en) * 1971-01-28 1975-01-22 Nat Res Dev Insulin derivatives
US3907763A (en) * 1972-03-01 1975-09-23 Bayer Ag Insulin derivatives crosslinked by a dicarboxylic acid moiety
DK319780A (da) * 1980-07-24 1982-01-25 Forenede Bryggerier As Fremgangsmaade til enzymatisk udskiftning af b-30 aminosyren i insuliner
IL68769A (en) * 1983-05-23 1986-02-28 Hadassah Med Org Pharmaceutical compositions containing insulin for oral administration
US5008241A (en) * 1985-03-12 1991-04-16 Novo Nordisk A/S Novel insulin peptides
JPH01254699A (ja) * 1988-04-05 1989-10-11 Kodama Kk インスリン誘導体及びその用途
AU8091091A (en) * 1990-07-26 1992-02-18 University Of Iowa Research Foundation, The Novel drug delivery systems for proteins and peptides using albumin as a carrier molecule
US5336782A (en) * 1991-04-24 1994-08-09 Kuraray Co., Ltd. Long chain carboxylic acid imide ester

Also Published As

Publication number Publication date
BR9407508A (pt) 1997-01-07
CN1133598A (zh) 1996-10-16
NO961070L (no) 1996-05-15
PT792290E (pt) 2002-01-30
CZ287945B6 (cs) 2001-03-14
SK32496A3 (en) 1996-11-06
PL178466B1 (pl) 2000-05-31
LU91101I2 (en) 2004-11-08
KR100310122B1 (ko) 2002-04-24
NL300160I1 (nl) 2004-12-01
RO112873B1 (ro) 1998-01-30
DE69428134D1 (de) 2001-10-04
DK0792290T3 (da) 2001-10-01
WO1995007931A1 (fr) 1995-03-23
CZ78996A3 (en) 1996-10-16
CA2171424A1 (fr) 1995-03-23
ATE204882T1 (de) 2001-09-15
JP2000060556A (ja) 2000-02-29
CA2171424C (fr) 2002-06-04
NO2004006I1 (no) 2004-10-11
FI117055B (fi) 2006-05-31
IL110977A (en) 2000-06-29
FI961220A0 (fi) 1996-03-15
EP0792290B1 (fr) 2001-08-29
NO961070D0 (no) 1996-03-15
JP2002308899A (ja) 2002-10-23
HU217684B (hu) 2000-03-28
RU2164520C2 (ru) 2001-03-27
NZ273285A (en) 1997-10-24
NO2004006I2 (fr) 2008-02-04
CN1056618C (zh) 2000-09-20
US5750497A (en) 1998-05-12
EP0792290A1 (fr) 1997-09-03
AU7652094A (en) 1995-04-03
JP3917333B2 (ja) 2007-05-23
BG61611B1 (bg) 1998-01-30
NL300160I2 (nl) 2005-07-01
DE122004000035I2 (de) 2009-08-06
AU682061B2 (en) 1997-09-18
JPH09502867A (ja) 1997-03-25
FR04C0020I2 (fr) 2005-05-27
EP1132404A2 (fr) 2001-09-12
ES2163451T3 (es) 2002-02-01
JP4060583B2 (ja) 2008-03-12
FI961220A (fi) 1996-05-14
NO2017041I2 (no) 2018-11-19
SK282495B6 (sk) 2002-02-05
NO316944B1 (no) 2004-07-05
NO2017041I1 (no) 2017-08-01
FR04C0020I1 (fr) 2004-10-29
IL110977A0 (en) 1994-11-28
UA45321C2 (uk) 2002-04-15
DE122004000035I1 (de) 2005-02-24
HUT75991A (en) 1997-05-28
PL313444A1 (en) 1996-07-08
KR960704925A (ko) 1996-10-09
HU9600676D0 (en) 1996-05-28
AU4846197A (en) 1998-02-19
BG100420A (bg) 1996-12-31
EP1132404A3 (fr) 2002-03-27
DE69428134T2 (de) 2002-05-02
JP3014764B2 (ja) 2000-02-28

Similar Documents

Publication Publication Date Title
NO2017041I2 (no) Insulin detemir
RU96108249A (ru) Ацилированный инсулин
NZ330700A (en) B27, B28, B29 (B chain) insulin derivatives having a rapid onset of action
PL322299A1 (en) Derivatives of insulin
CA2081659A1 (fr) Derives du facteur humain recombinant viii
CA2138161A1 (fr) Peptide de type glucagon et derives insulinotropine
AU566180B2 (en) Human pancreatic grf
PT83278A (en) Process for the preparation of insulin analogues and of injectable insulin solutions containing the same
SG47913A1 (en) Substitution analogues of magainin peptides
DK119391A (da) Humaninsulinanaloger